Table 1 Currently available bypassing... | American Society of Hematology

Table 1

Currently available bypassing agents for treatment and prevention of bleeding

	Recombinant fVIIa	aPCC
Contents	fVIIa	fII, fIX, and fX and fVIIa and fXa
Mechanism of action	Activate fX on the platelet surface	Action of fXa and fII
Half-life	2-3 h	8-12 h
Infusion volume*	5 mL	∼90 mL
Bleeding treatment⁴⁴
Dose/frequency	90-120 μg/kg every 2-3 h (or 270 μg/kg × 1)	50-100 U/kg every 8-12 h
Efficacy	∼80%	∼80%
Prophylaxis^24,26
Dose/frequency	90 or 270 μg/kg/d	85 U/kg 3 times/wk
Efficacy	45%–59% reduction in bleeding frequency	62% overall reduction in bleeding frequency†

	Recombinant fVIIa	aPCC
Contents	fVIIa	fII, fIX, and fX and fVIIa and fXa
Mechanism of action	Activate fX on the platelet surface	Action of fXa and fII
Half-life	2-3 h	8-12 h
Infusion volume*	5 mL	∼90 mL
Bleeding treatment⁴⁴
Dose/frequency	90-120 μg/kg every 2-3 h (or 270 μg/kg × 1)	50-100 U/kg every 8-12 h
Efficacy	∼80%	∼80%
Prophylaxis^24,26
Dose/frequency	90 or 270 μg/kg/d	85 U/kg 3 times/wk
Efficacy	45%–59% reduction in bleeding frequency	62% overall reduction in bleeding frequency†

Based on a 50 kg person receiving 5mg of rFVIIa or 4000 U of aPCC.

An 84% reduction in the group of patients with good response and 28% reduction in group of patients with poor response.